PR87759

MONTREAL, Jan. 26, 2021 /PRNewswire=KYODO JBN/--

Caprion-HistoGeneX, a leading global provider of specialized precision medicine

laboratory services to the biopharmaceutical industry, is pleased to announce

its new corporate name, CellCarta, and brand identity.

Photo -

https://mma.prnewswire.com/media/1426440/Caprion_Biosciences_Precision_Medicine_Leader_Caprion_HistoGeneX.jpg

Logo -

https://mma.prnewswire.com/media/1426437/Caprion_Biosciences_Precision_Medicine_Leader_Caprion_HistoGeneX.jpg

The new name for the Montreal-headquartered company stems from the 2019

combination of contract research organization Caprion Biosciences, which

specializes in immunology and proteomics services, and HistoGeneX, a provider

of histopathology and genomics services based in Antwerp. Recently, CellCarta

further expanded its scientific capabilities and geographic presence through

the acquisitions of Nova Scotia-based Clinical Logistics Inc. and

California-based Mosaic Laboratories LLC. As a result, CellCarta is well

positioned to serve the global clinical trial requirements of its

pharmaceutical and bio-tech clients with state-of-the-art facilities in the

United States, Canada, Europe and China.  CellCarta is backed by Arsenal

Capital Partners.

The name CellCarta is inspired by the Magna Carta, a symbol of individual

liberty, and is meant to evoke the company's mission of mapping the content and

function of human cells to enable and accelerate the evolution of personalized

precision medicine.

"Our mission is to be the global partner of choice for biopharmaceutical

companies seeking precision medicine solutions to help ensure a healthier

future for us all," said Martin LeBlanc, CEO of CellCarta. "By uniting our

diverse teams of scientists across the world under a common brand identity, we

aim to articulate a single message aligned with our shared set of fundamental

values focused on scientific excellence, a collaborative mindset and a

commitment to deliver high quality results to our partners. It also further

reinforces our commitment to provide our clients with a broad and integrated

set of services under a single organization."

The new brand identity was developed in conjunction with BrandBourg, a Canadian

consultancy firm specializing in brand strategy and brand identity.

CellCarta's visual identity is intended to be reminiscent of a map or puzzle

representing the distinctions between human cells. It is further meant to

convey a brand personality that is innovative, trustworthy and embodies

scientific leadership.

"We wanted to create a brand that is unique in the market, relevant to our

clients and inspiring to our employees around the world," said Nick Wright,

President and COO of CellCarta. "CellCarta embodies everything we do, which is

about mapping differences between cells and ultimately between individuals, so

that our partners can develop better and more targeted therapies."

David Spaight, Executive Chairman of CellCarta and an Arsenal Operating

Partner, added, "By uniting under a single brand identity, CellCarta is sending

a signal that its rapid expansion through acquisitions and organic growth has

resulted in a market-leading enterprise that is greater than the sum of its

parts. The ongoing success of CellCarta exemplifies Arsenal's 'Strategic

Company Building' approach that focuses on expanding a company's solution

offering, elevating its market position, and compounding its growth."

The following video further describes CellCarta's new brand identity:

www.cellcarta.com

About CellCarta

CellCarta is a leading provider of specialized precision medicine laboratory

services to the biopharmaceutical industry. Leveraging its integrated

analytical platforms in immunology, histopathology, proteomics and genomics, as

well as related specimen collection and logistics services, CellCarta supports

the entire drug development cycle, from discovery to late-stage clinical

trials. The company operates globally with with over 700 employees in its nine

facilities located in Canada, USA, Belgium, Australia, and China. For more

information: www.cellcarta.com

About Arsenal Capital Partners

Arsenal is a leading private equity firm that specializes in investments in

middle-market healthcare and industrials companies.  Since its inception in

2000, Arsenal has raised institutional equity investment funds of $5.3 billion,

has completed more than 200 platform and add-on investments, and achieved more

than 30 realizations. Arsenal healthcare companies focus on improving critical

healthcare processes and scientific requirements leading to improved outcomes

for patients.  The firm works with management teams to build strategically

important companies with leading market positions, high growth and high

value-add. For more information: www.arsenalcapital.com

Media Contact: CellCarta

               Guylaine Galipeau

               Global Marketing Director, CellCarta

               ggalipeau@caprion.com;

Media Contact for Arsenal Capital Partners:

               Prosek Partners

               Kristen Duarte

               kduarte@prosek.com

SOURCE: Caprion Biosciences Inc.